000			02154 a2200613 4500
005			20250515140054.0
264		0	_c20090206
008			200902s 0 0 eng d
022			_a1476-5551
024	7		_a10.1038/leu.2008.261 _2doi
040			_aNLM _beng _cNLM
100	1		_aBuske, C
245	0	0	_aThe addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). _h[electronic resource]
260			_bLeukemia _cJan 2009
300			_a153-61 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAntibodies, Monoclonal _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal, Murine-Derived
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use
650	0	4	_aCyclophosphamide _xtherapeutic use
650	0	4	_aDisease-Free Survival
650	0	4	_aDoxorubicin _xtherapeutic use
650	0	4	_aHumans
650	0	4	_aMiddle Aged
650	0	4	_aPrednisone _xtherapeutic use
650	0	4	_aRemission Induction
650	0	4	_aRituximab
650	0	4	_aTreatment Outcome
650	0	4	_aVincristine _xtherapeutic use
650	0	4	_aWaldenstrom Macroglobulinemia _xdrug therapy
700	1		_aHoster, E
700	1		_aDreyling, M
700	1		_aEimermacher, H
700	1		_aWandt, H
700	1		_aMetzner, B
700	1		_aFuchs, R
700	1		_aBittenbring, J
700	1		_aWoermann, B
700	1		_aHohloch, K
700	1		_aHess, G
700	1		_aLudwig, W-D
700	1		_aSchimke, J
700	1		_aSchmitz, S
700	1		_aKneba, M
700	1		_aReiser, M
700	1		_aGraeven, U
700	1		_aKlapper, W
700	1		_aUnterhalt, M
700	1		_aHiddemann, W
773	0		_tLeukemia _gvol. 23 _gno. 1 _gp. 153-61
856	4	0	_uhttps://doi.org/10.1038/leu.2008.261 _zAvailable from publisher's website
999			_c18285732 _d18285732